https://doi.org/10.55788/f1a188f8
“Evidence indicates that artificial intelligence improves ADR, particularly in small non-advanced lesions,” said Mr Oswaldo Ortiz (Hospital Clinic Barcelona, Spain) [1]. “In patients with Lynch syndrome, it is extra important to detect every adenoma, since these patients tend to progress faster towards adenocarcinoma” [2]. Mr Ortiz and colleagues designed a randomised-controlled trial to compare the performance of CADe colonoscopy with WLE in 430 participants with Lynch syndrome [3]. Adenoma per colonoscopy was the primary endpoint of the study.
The mean adenoma per colonoscopy was 0.64 in both study arms, showing no difference between the 2 study procedures (RR 1.00; 95% CI 0.73–1.27; P=0.42). Stratifying the outcomes by location, size, or morphology did not reveal significant differences between the 2 study arms. Also, polyp detection rates and ADR were similar for the 2 interventions. However, the rate of serrated lesions per colonoscopy was higher in the CADe arm than in the WLE arm (0.58 vs 0.46; RR 1.26; P=0.01). Finally, Mr Ortiz noted that the false positive rate was higher in the CADe arm than in the WLE arm (0.21 vs 0.08; RR 2.8; P=0.04).
- Hassan C, et al. Ann Intern Med. 2023;176:1209–1220.
- Ahadova A, et al. Int J. Cancer. 2021;148:800–811.
- Ortiz O, et al. Evaluation of artificial intelligence-assisted colonoscopy for adenoma detection in Lynch syndrome: a multicentre randomized controlled trial (timely study). LB15, UEG Week 2023, 14–17 October, Copenhagen, Denmark.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Can computer technology improve our everyday colonoscopy results? Next Article
Epinephrine boosts efficiency in gastric ESD »
« Can computer technology improve our everyday colonoscopy results? Next Article
Epinephrine boosts efficiency in gastric ESD »
Table of Contents: UEGW 2023
Featured articles
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
What’s New in Artificial Intelligence
Digital intervention relieves symptoms and improves QoL in IBS
GastroGPT: Successful proof-of-concept study of gastroenterology-specific large language model
Other Therapeutics and Outcomes
Primary results from MAESTRO-NASH trial: resmetirom efficacious for NASH
Apraglutide: Advancing the treatment of short bowel syndrome
Endobiliary radiofrequency ablation in pCCA: a pilot study
Raising awareness for microscopic colitis: disease course and predictors
Outcomes of IBD Trials
DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
Guselkumab provides benefits in UC regardless of advanced therapy history
INSPIRE: Risankizumab meets all efficacy endpoints in UC
Risankizumab resolves extraintestinal manifestations in CD
Obefazimod takes the spotlight as promising UC treatment
Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease
LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history
ARTEMIS-UC: New kid in town for UC
Breakthroughs in Colorectal Lesions
Safer removal of large polyps with cold snare technique
Higher recurrence rates with cold snare EMR than with conventional EMR
How to deal with at-risk patients above the CRC screening age limit?
European CRC screening needs to be revised
Advances in Upper Endoscopy and Colonoscopy
Epinephrine boosts efficiency in gastric ESD
Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome
Can computer technology improve our everyday colonoscopy results?
Is AI-assisted colonoscopy ready for clinical practice?
Should we use E-SEMS or EVT for traumatic oesophageal perforations?
Related Articles
March 21, 2022
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com